Abstract
Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D3, producing 20S-hydroxyvitamin D3 [20(OH)D3] and 20S,23-dihydroxyvitamin D3 [20,23(OH)2D3] as the major metabolites. These are biologically active, acting as partial vitamin D receptor (VDR) agonists. Minor products include 17-hydroxyvitamin D3, 17,20-dihydroxyvitamin D3, and 17,20,23-trihydroxyvitamin D3. In the current study, we have further analyzed the reaction products from cytochrome P450scc (P450scc) action on vitamin D3 and have identified two 22-hydroxy derivatives as products, 22-hydroxyvitamin D3 [22(OH)D3] and 20S,22-dihydroxyvitamin D3 [20,22(OH)2D3]. The structures of both of these derivatives were determined by NMR. P450scc could convert purified 22(OH)D3 to 20,22(OH)2D3. The 20,22(OH)2D3 could also be produced from 20(OH)D3 and was metabolized to a trihydroxyvitamin D3 product. We compared the biological activities of these new derivatives with those of 20(OH)D3, 20,23(OH)2D3, and 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3]. 1,25(OH)2D3, 20(OH)D3, 22(OH)D3, 20,23(OH)2D3, and 20,22(OH)2D3 significantly inhibited keratinocyte proliferation in a dose-dependent manner. The strongest inducers of involucrin expression (a marker of keratinocyte differentiation) were 20,23(OH)2D3, 20,22(OH)2D3, 20(OH)D3, and 1,25(OH)2D3, with 22(OH)D3 having a heterogeneous effect. Little or no stimulation of CYP24 mRNA expression was observed for all the analogs tested except for 1,25(OH)2D3. All the compounds stimulated VDR translocation from the cytoplasm to the nucleus with 22(OH)D3 and 20,22(OH)2D3 having less effect than 1,25(OH)2D3 and 20(OH)D3. Thus, we have identified 22(OH)D3 and 20,22(OH)2D3 as products of CYP11A1 action on vitamin D3 and shown that, like 20(OH)D3 and 20,23(OH)2D3, they are active on keratinocytes via the VDR, however, showing a degree of phenotypic heterogeneity in comparison with other P450scc-derived hydroxy metabolites of vitamin D3.
Footnotes
This work was supported by the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases [Grant R01-AR052190] (to A.S.); the University of Western Australia; and the College of Pharmacy at the University of Tennessee Health Science Center.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.111.040071.
↵ The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- P450scc
- cytochrome P450scc
- 20(OH)D3
- 20-hydroxyvitamin D3
- 20,23(OH)2D3
- 20,23-dihydroxyvitamin D3
- 17,20,23(OH)3D3
- 17,20,23-trihydroxyvitamin D3
- 20,22(OH)2D3
- 20,22-dihydroxyvitamin D3
- 23(OH)D3
- 23-hydroxyvitamin D3
- 17,20(OH)2D3
- 17,20-dihydroxyvitamin D3
- 1,25(OH)2D3
- 1α,25-dihydroxyvitamin D3
- 22(OH)D3
- 22-hydroxyvitamin D3
- PCR
- polymerase chain reaction
- TLC
- thin-layer chromatography
- cyclodextrin
- 2-hydroxypropyl-β-cyclodextrin
- COSY
- correlation spectroscopy
- TOCSY
- total correlation spectroscopy
- HSQC
- heteronuclear single quantum correlation spectroscopy
- HMBC
- heteronuclear multiple bond correlation spectroscopy
- HaCaT
- human epidermal keratinocytes
- VDR
- vitamin D receptor
- 25(OH)D3
- 25-hydroxyvitamin D3
- ANOVA
- analysis of variance.
- Received April 16, 2011.
- Accepted June 15, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|